Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | Cath Lab| November 05, 2015

Trends and New Technology at Transcatheter Cardiovascular Therapeutics (TCT)

For the past few years, the focus of the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings has been on structural heart advances, and the traditional focus on percutaneous coronary intervention (PCI) appeared to take a back seat to make way for the flood of data and new transcatheter valve technologies. While valves are still at the forefront, this year the focus again returned to workhorse PCI stents due to new stents in development and advances in bioresorbable technologies. 

Watch the video Editor's Choice of the Most Innovative New Technologies at TCT 2015

The Boston Scientific Synergy stent gained U.S. Food and Drug Administration (FDA) clearance the week before TCT, becoming the first metallic drug-eluting stent (DES) that uses a bioresorbable drug carrier polymer.  The abluminal polymer coating completely dissolves within three months, eliminating long-term issues related to permanent polymers, which can cause vessel irritation leading to in-stent restenosis and late-stent thrombosis. The Synergy’s approval was widely discussed as a key advancement in DES technology. 

The key late-breaker at TCT was the ABSORB III trial, which is the pivotal FDA study for the Abbott Absorb completely bioresorbable DES. The data show the Absorb had outcomes statistically equal to the Abbott Xience V stent, which to date has the best clinical outcomes data for any DES. 

“There were no statistical differences between the devices for target lesion failure or any of its components,” said Dean Kereiakes, M.D., medical director of  The Christ Hospital Heart and Vascular Center, and a lead investigator for ABSORB III. He said the trial was designed to show non-inferiority to Xience at one year, but the stent itself is designed to improve long-term outcomes to avoid the 2-3 percent per year of stent-related issues (strut fracture, in-stent restenosis, late-stent thrombosis). “The real test is in the long run if the Absorb bioresorbable scaffold improves late outcomes when it’s gone compared to a metal platform,” he explained.

Watch video interview with Kereiakes regarding the ABSORB III trial and Synergy stents

Additional positive data was presented on the bioresorbable stents from the late-breaking ABSORB China, ABSORB II and BIOSOLVE II trials.

Advances in transcatheter valves also were among the major advances at  TCT. Continued positive clinical data from both the Medtronic CoreValve and Edwards Lifesciences’ Sapien valves were presented, including information on the new FDA valve-in-valve indication, and data on improved versions of both valves. Numerous sessions focused on new technologies in development or entering trials for transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR) and tricuspid valve replacement (TTVR). Sessions on mitral and tricuspid valves were packed to capacity again this year, as both of these technologies are seen as key paradigm shifts in the standard of care. With the overwhelming success of TAVR, many TCT experts predict transcatheter valve technologies will largely replace open-heart surgical valves and repairs in the coming years. 

Watch video on these and other trends at TCT 2015 with MDBuyLine's Tom Watson


Here are links to additional video interviews conducted at TCT 2015:

Drug-Filled Stents as an Alternative to Polymer Drug Carriers at TCT 2015

Lithoplasty as an Alternative to Treat Calcified Lesions at TCT 2015

Eye-tracking For Dose Reduction in the Cath Lab — TCT 2015

New Approaches to Denervation Therapy at TCT 2015

Update on U.S. Transradial Access Adoption With Sunil Rao at TCT 2015

Advances in Interventional Heart Failure Hemodynamic Support — TCT 2015

Advances in Intravascular Imaging at TCT 2015

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init